Changshan Pharmaceutical: Enoxaparin Sodium Injection Receives Tajikistan Drug Registration Certificate

2026-04-12 03:21:03

Changshan Pharmaceutical announces that the company’s drug, Enoxaparin Sodium Injection, has recently received a drug registration certificate issued by the Tajikistan drug regulatory authority. This medication is used to prevent venous thromboembolism, treat deep vein thrombosis, and in combination with aspirin for the treatment of unstable angina. The approval of this registration document will have a positive impact on the company’s expansion into overseas markets.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes